SBE13, a newly identified inhibitor of inactive polo-like kinase 1 by Sarah Keppner et al.
POSTER PRESENTATION Open Access
SBE13, a newly identified inhibitor of inactive
polo-like kinase 1
Sarah Keppner1*, Ewgenij Proschak2, Gisbert Schneider2, B Spänkuch1
From 5th German Conference on Cheminformatics: 23. CIC-Workshop
Goslar, Germany. 8-10 November 2009
Protein kinases are important targets for drug develop-
ment. The almost identical protein folding of kinases
and the common co-substrate ATP leads to the problem
of inhibitor selectivity. Type II inhibitors, targeting the
inactive conformation of kinases, occupy a hydrophobic
pocket with less conserved surrounding amino acids [1].
Human polo-like kinase 1 (Plk1) represents a promis-
ing target for approaches to identify new therapeutic
agents. Plk1 belongs to a family of highly conserved ser-
ine/threonine kinases, and is a key player in mitosis,
where it modulates the spindle checkpoint at meta-
phase/anaphase transition. Plk1 is over-expressed in all
today analyzed human tumors of different origin and
serves as a negative prognostic marker in cancer
patients. The newly identified inhibitor, SBE13, a vanillin
derivative, targets Plk1 in its inactive conformation [2].
This leads to selectivity within the Plk family and
towards Aurora A. This selectivity can be explained by
docking studies of SBE13 into the binding pocket of
homology models of Plk1, Plk2 and Plk3 in their inac-
tive conformation.
SBE13 showed anti-proliferative effects in cancer cell
lines of different origins with EC50 values between 5 μM
and 39 μM and induced apoptosis. Increasing concen-
trations of SBE13 result in increasing amounts of cells
in G2/M phase 13 hours after double thymidin block of
HeLa cells. The kinase activity of Plk1 was inhibited
with an IC50 of 200 pM.
Taken together, we could show that carefully designed
structure-based virtual screening is well-suited to iden-
tify selective type II kinase inhibitors targeting Plk1 as
potential anti-cancer therapeutics.
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